Clinical Trials Logo
  1. Home
  2. Infections, Respiratory Tract
  3. NCT02000765

A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects

Infections, Respiratory Tract Clinical Trial

Official title:
An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774)

Clinical Trial Summary

This is an open-label, non-randomized, two-period, cross-over, mass balance study that will evaluate the recovery, excretion, and pharmacokinetics of a single intravenous (IV) dose of [14C]-GSK2140944 (Period 1) and a single oral dose of [14C]-GSK2140944 ( Period 2) in 6 healthy male subjects. The results from this study will aid in the design of future clinical pharmacology studies such as the thorough corrected QT interval study, special population studies (renal, hepatic, critically ill patients), potential drug interaction studies, and will help to establish safe and efficacious intravenous and oral dosing regimens.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02000765
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date November 8, 2013
Completion date November 30, 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02202187 - A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers Phase 1
Completed NCT02257398 - Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers Phase 1
Completed NCT01706315 - This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects Phase 1
Completed NCT04600752 - Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India Phase 4
Terminated NCT01292213 - A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom N/A
Completed NCT01772238 - Bioequivalence Study of an Amoxicillin-Clavulanic Phase 1
Completed NCT01615796 - Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses Phase 1
Completed NCT02169583 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Phase 1
Completed NCT01353768 - Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study N/A
Completed NCT01767571 - Bioequivalence Study of Cephalexin Suspension 250 Phase 1
Completed NCT01767532 - Bioequivalence Study of Cephalexin Suspension 125 Phase 1
Completed NCT01510938 - Probiotics in Respiratory Tract Infections in Children Phase 2
Completed NCT00354965 - Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients Phase 1
Completed NCT02688361 - A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution Phase 1
Withdrawn NCT02730364 - An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu Phase 3
Withdrawn NCT02678234 - An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu Phase 3
Completed NCT01767584 - Bioequivalence Study of Cephalexin Tablets 1g Phase 1